BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tanaka T, Takata K, Yokoyama K, Fukuda H, Yamauchi R, Fukunaga A, Shakado S, Sakisaka S, Hirai F. Pretreatment Modified Albumin–Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma. Current Oncology 2022;29:4799-4810. [DOI: 10.3390/curroncol29070381] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Psilopatis I, Damaskos C, Garmpi A, Sarantis P, Koustas E, Antoniou EA, Dimitroulis D, Kouraklis G, Karamouzis MV, Vrettou K, Marinos G, Kontzoglou K, Garmpis N. FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far? Int J Mol Sci 2023;24. [PMID: 36769004 DOI: 10.3390/ijms24032685] [Reference Citation Analysis]
2 Tian BW, Yan LJ, Ding ZN, Liu H, Han CL, Meng GX, Xue JS, Dong ZR, Yan YC, Hong JG, Chen ZQ, Wang DX, Li T. Evaluating liver function and the impact of immune checkpoint inhibitors in the prognosis of hepatocellular carcinoma patients: A systemic review and meta-analysis. Int Immunopharmacol 2023;114:109519. [PMID: 36459922 DOI: 10.1016/j.intimp.2022.109519] [Reference Citation Analysis]
3 . Atezolizumab/bevacizumab. Reactions Weekly 2022;1921:52-52. [DOI: 10.1007/s40278-022-22046-z] [Reference Citation Analysis]